Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study

Ennio Lubrano; Fabio Massimo Perrotta; Maria Manara; Salvatore D’Angelo; Olga Addimanda; Roberta Ramonda; Leonardo Punzi; Ignazio Olivieri; Carlo Salvarani; Antonio Marchesoni

doi:10.3899/jrheum.160363

REFERENCES

1.↵
1. Rudwaleit M,
2. van der Heijde D,
3. Landewé R,
4. Listing J,
5. Akkoc N,
6. Brandt J,
7. et al.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.
OpenUrl Abstract/FREE Full Text
2.↵
1. Sieper J,
2. Lenaerts J,
3. Wollenhaupt J,
4. Rudwaleit M,
5. Mazurov VI,
6. Myasoutova L,
7. et al;
8. All INFAST Investigators
. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014;73:101–7.
OpenUrl Abstract/FREE Full Text
3.↵
1. Song IH,
2. Weiß A,
3. Hermann KG,
4. Haibel H,
5. Althoff CE,
6. Poddubnyy D,
7. et al.
Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013;72:823–5.
OpenUrl Abstract/FREE Full Text
4.↵
1. Sieper J,
2. van der Heijde D,
3. Dougados M,
4. Mease PJ,
5. Maksymowych WP,
6. Brown MA,
7. et al.
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815–22.
OpenUrl Abstract/FREE Full Text
5.↵
1. van der Heijde D,
2. Sieper J,
3. Maksymowych WP,
4. Dougados M,
5. Burgos-Vargas R,
6. Landewé R,
7. et al;
8. Assessment of SpondyloArthritis international Society
. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905–8.
OpenUrl Abstract/FREE Full Text
6.↵
1. Lubrano E,
2. Perrotta FM,
3. Marchesoni A,
4. D’Angelo S,
5. Ramonda R,
6. Addimanda O,
7. et al.
Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 2015;42:258–63.
OpenUrl Abstract/FREE Full Text
7.↵
1. Spadaro A,
2. Lubrano E,
3. Marchesoni A,
4. D’Angelo S,
5. Ramonda R,
6. Addimanda O,
7. et al.
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology 2013;52:1914–9.
OpenUrl Abstract/FREE Full Text
8.↵
1. Anderson JJ,
2. Baron G,
3. van der Heijde D,
4. Felson DT,
5. Dougados M
. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876–86.
OpenUrl CrossRef PubMed
9.↵
1. Lukas C,
2. Landewé R,
3. Sieper J,
4. Dougados M,
5. Davis J,
6. Braun J,
7. et al;
8. Assessment of SpondyloArthritis international Society
. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24.
OpenUrl Abstract/FREE Full Text
10.↵
1. Machado P,
2. Landewé R,
3. Lie E,
4. Kvien TK,
5. Braun J,
6. Baker D,
7. et al;
8. Assessment of SpondyloArthritis international Society
. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47–53.
OpenUrl Abstract/FREE Full Text
11.↵
1. Zochling J,
2. Braun J
. Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006;24 Suppl 43:S-88–92.
OpenUrl
12.↵
1. Landewé R,
2. Braun J,
3. Deodhar A,
4. Dougados M,
5. Maksymowych WP,
6. Mease PJ,
7. et al.
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39–47.
OpenUrl Abstract/FREE Full Text
13.↵
1. Garrett S,
2. Jenkinson T,
3. Kennedy LG,
4. Whitelock H,
5. Gaisford P,
6. Calin A
. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
OpenUrl PubMed
14.↵
1. Godfrin-Valnet M,
2. Prati C,
3. Puyraveau M,
4. Toussirot E,
5. Letho-Gyselink H,
6. Wendling D
. Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. Joint Bone Spine 2013;80:393–8.
OpenUrl CrossRef PubMed
15.↵
1. Brophy S,
2. Calin A
. Definition of disease flare in ankylosing spondylitis: the patients’ perspective. J Rheumatol 2002;29:954–8.
OpenUrl Abstract/FREE Full Text
16.↵
1. Cooksey R,
2. Brophy S,
3. Gravenor MB,
4. Brooks CJ,
5. Burrows CL,
6. Siebert S
. Frequency and characteristics of disease flares in ankylosing spondylitis. Rheumatology 2010;49:929–32.
OpenUrl Abstract/FREE Full Text
17.↵
1. Jenkinson TR,
2. Mallorie PA,
3. Whitelock HC,
4. Kennedy LG,
5. Garrett SL,
6. Calin A
. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.
OpenUrl PubMed
18.↵
1. Calin A,
2. Garrett S,
3. Whitelock H,
4. Kennedy LG,
5. O’Hea J,
6. Mallorie P,
7. et al.
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.
OpenUrl PubMed
19.↵
1. van der Linden S,
2. Valkenburg HA,
3. Cats A
. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
OpenUrl CrossRef PubMed
20.↵
1. Smolen JS,
2. Braun J,
3. Dougados M,
4. Emery P,
5. Fitzgerald O,
6. Helliwell P,
7. et al.
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16.
OpenUrl Abstract/FREE Full Text
21.↵
1. van Tubergen A,
2. van der Heijde D,
3. Anderson J,
4. Landewé R,
5. Dougados M,
6. Braun J,
7. et al.
Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis 2003;62:215–21.
OpenUrl Abstract/FREE Full Text
22.↵
1. Stone MA,
2. Inman RD,
3. Wright JG,
4. Maetzel A
. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 2004;51:316–20.
OpenUrl CrossRef PubMed
23.↵
1. Glintborg B,
2. Ostergaard M,
3. Krogh NS,
4. Dreyer L,
5. Kristensen HL,
6. Hetland ML
. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69:2002–8.
OpenUrl Abstract/FREE Full Text
24.↵
1. Heinonen AV,
2. Aaltonen KJ,
3. Joensuu JT,
4. Lähteenmäki JP,
5. Pertovaara MI,
6. Romu MK,
7. et al.
Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol 2015;42:2339–46.
OpenUrl Abstract/FREE Full Text
25.↵
1. Lorenzin M,
2. Ortolan A,
3. Frallonardo P,
4. Oliviero F,
5. Punzi L,
6. Ramonda R
. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord 2015;16:166.
OpenUrl CrossRef PubMed
26.↵
1. Sieper J,
2. Lenaerts J,
3. Wollenhaupt J,
4. Rudwaleit M,
5. Mazurov VI,
6. Myasoutova L,
7. et al;
8. All INFAST Investigators
. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 2014;73:108–13.
OpenUrl Abstract/FREE Full Text
27.↵
1. Song IH,
2. Althoff CE,
3. Haibel H,
4. Hermann KG,
5. Poddubnyy D,
6. Listing J,
7. et al.
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012;71:1212–5.
OpenUrl Abstract/FREE Full Text
28.↵
1. Gossec L,
2. Portier A,
3. Landewé R,
4. Etcheto A,
5. Navarro-Compán V,
6. Kroon F,
7. et al.
Preliminary definitions of ‘flare’ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Ann Rheum Dis 2016 Feb 4 (E-pub ahead of print).
29.↵
1. Godfrin-Valnet M,
2. Puyraveau M,
3. Prati C,
4. Wendling D
. Flare in spondyloarthritis: thresholds of disease activity variations. Joint Bone Spine 2015;82:192–5.
OpenUrl CrossRef PubMed
30.↵
1. Wendling D,
2. Prati C
. Flare in axial spondyloarthritis. The dark side of the outcome. Ann Rheum Dis 2016 March 15 (E-pub ahead of print).

In this issue

Download PDF

Tweet Widget

Bookmark this article

Keywords

AXIAL SPONDYLOARTHRITIS

REMISSION

ANTI-TNF-α DRUGS

DISEASE FLARES

Cited By...

More in this TOC Section

Show more Article

Keywords

[1] 1.↵
Rudwaleit M,
van der Heijde D,
Landewé R,
Listing J,
Akkoc N,
Brandt J,
et al.
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777–83.
OpenUrl Abstract/FREE Full Text

[2] Rudwaleit M,

[3] van der Heijde D,

[4] Landewé R,

[5] Listing J,

[6] Akkoc N,

[7] Brandt J,

[8] et al.

[9] 2.↵
Sieper J,
Lenaerts J,
Wollenhaupt J,
Rudwaleit M,
Mazurov VI,
Myasoutova L,
et al;
All INFAST Investigators
. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 2014;73:101–7.
OpenUrl Abstract/FREE Full Text

[10] Sieper J,

[11] Lenaerts J,

[12] Wollenhaupt J,

[13] Rudwaleit M,

[14] Mazurov VI,

[15] Myasoutova L,

[16] et al;

[17] All INFAST Investigators

[18] 3.↵
Song IH,
Weiß A,
Hermann KG,
Haibel H,
Althoff CE,
Poddubnyy D,
et al.
Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis 2013;72:823–5.
OpenUrl Abstract/FREE Full Text

[19] Song IH,

[20] Weiß A,

[21] Hermann KG,

[22] Haibel H,

[23] Althoff CE,

[24] Poddubnyy D,

[25] et al.

[26] 4.↵
Sieper J,
van der Heijde D,
Dougados M,
Mease PJ,
Maksymowych WP,
Brown MA,
et al.
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815–22.
OpenUrl Abstract/FREE Full Text

[27] Sieper J,

[28] van der Heijde D,

[29] Dougados M,

[30] Mease PJ,

[31] Maksymowych WP,

[32] Brown MA,

[33] et al.

[34] 5.↵
van der Heijde D,
Sieper J,
Maksymowych WP,
Dougados M,
Burgos-Vargas R,
Landewé R,
et al;
Assessment of SpondyloArthritis international Society
. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905–8.
OpenUrl Abstract/FREE Full Text

[35] van der Heijde D,

[36] Sieper J,

[37] Maksymowych WP,

[38] Dougados M,

[39] Burgos-Vargas R,

[40] Landewé R,

[41] et al;

[42] Assessment of SpondyloArthritis international Society

[43] 6.↵
Lubrano E,
Perrotta FM,
Marchesoni A,
D’Angelo S,
Ramonda R,
Addimanda O,
et al.
Remission in nonradiographic axial spondyloarthritis treated with anti-tumor necrosis factor-α drugs: an Italian multicenter study. J Rheumatol 2015;42:258–63.
OpenUrl Abstract/FREE Full Text

[44] Lubrano E,

[45] Perrotta FM,

[46] Marchesoni A,

[47] D’Angelo S,

[48] Ramonda R,

[49] Addimanda O,

[50] et al.

[51] 7.↵
Spadaro A,
Lubrano E,
Marchesoni A,
D’Angelo S,
Ramonda R,
Addimanda O,
et al.
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology 2013;52:1914–9.
OpenUrl Abstract/FREE Full Text

[52] Spadaro A,

[53] Lubrano E,

[54] Marchesoni A,

[55] D’Angelo S,

[56] Ramonda R,

[57] Addimanda O,

[58] et al.

[59] 8.↵
Anderson JJ,
Baron G,
van der Heijde D,
Felson DT,
Dougados M
. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876–86.
OpenUrl CrossRef PubMed

[60] Anderson JJ,

[61] Baron G,

[62] van der Heijde D,

[63] Felson DT,

[64] Dougados M

[65] 9.↵
Lukas C,
Landewé R,
Sieper J,
Dougados M,
Davis J,
Braun J,
et al;
Assessment of SpondyloArthritis international Society
. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:18–24.
OpenUrl Abstract/FREE Full Text

[66] Lukas C,

[67] Landewé R,

[68] Sieper J,

[69] Dougados M,

[70] Davis J,

[71] Braun J,

[72] et al;

[73] Assessment of SpondyloArthritis international Society

[74] 10.↵
Machado P,
Landewé R,
Lie E,
Kvien TK,
Braun J,
Baker D,
et al;
Assessment of SpondyloArthritis international Society
. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47–53.
OpenUrl Abstract/FREE Full Text

[75] Machado P,

[76] Landewé R,

[77] Lie E,

[78] Kvien TK,

[79] Braun J,

[80] Baker D,

[81] et al;

[82] Assessment of SpondyloArthritis international Society

[83] 11.↵
Zochling J,
Braun J
. Remission in ankylosing spondylitis. Clin Exp Rheumatol 2006;24 Suppl 43:S-88–92.
OpenUrl

[84] Zochling J,

[85] Braun J

[86] 12.↵
Landewé R,
Braun J,
Deodhar A,
Dougados M,
Maksymowych WP,
Mease PJ,
et al.
Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study. Ann Rheum Dis 2014;73:39–47.
OpenUrl Abstract/FREE Full Text

[87] Landewé R,

[88] Braun J,

[89] Deodhar A,

[90] Dougados M,

[91] Maksymowych WP,

[92] Mease PJ,

[93] et al.

[94] 13.↵
Garrett S,
Jenkinson T,
Kennedy LG,
Whitelock H,
Gaisford P,
Calin A
. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–91.
OpenUrl PubMed

[95] Garrett S,

[96] Jenkinson T,

[97] Kennedy LG,

[98] Whitelock H,

[99] Gaisford P,

[100] Calin A

[101] 14.↵
Godfrin-Valnet M,
Prati C,
Puyraveau M,
Toussirot E,
Letho-Gyselink H,
Wendling D
. Evaluation of spondylarthritis activity by patients and physicians: ASDAS, BASDAI, PASS, and flares in 200 patients. Joint Bone Spine 2013;80:393–8.
OpenUrl CrossRef PubMed

[102] Godfrin-Valnet M,

[103] Prati C,

[104] Puyraveau M,

[105] Toussirot E,

[106] Letho-Gyselink H,

[107] Wendling D

[108] 15.↵
Brophy S,
Calin A
. Definition of disease flare in ankylosing spondylitis: the patients’ perspective. J Rheumatol 2002;29:954–8.
OpenUrl Abstract/FREE Full Text

[109] Brophy S,

[110] Calin A

[111] 16.↵
Cooksey R,
Brophy S,
Gravenor MB,
Brooks CJ,
Burrows CL,
Siebert S
. Frequency and characteristics of disease flares in ankylosing spondylitis. Rheumatology 2010;49:929–32.
OpenUrl Abstract/FREE Full Text

[112] Cooksey R,

[113] Brophy S,

[114] Gravenor MB,

[115] Brooks CJ,

[116] Burrows CL,

[117] Siebert S

[118] 17.↵
Jenkinson TR,
Mallorie PA,
Whitelock HC,
Kennedy LG,
Garrett SL,
Calin A
. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694–8.
OpenUrl PubMed

[119] Jenkinson TR,

[120] Mallorie PA,

[121] Whitelock HC,

[122] Kennedy LG,

[123] Garrett SL,

[124] Calin A

[125] 18.↵
Calin A,
Garrett S,
Whitelock H,
Kennedy LG,
O’Hea J,
Mallorie P,
et al.
A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281–5.
OpenUrl PubMed

[126] Calin A,

[127] Garrett S,

[128] Whitelock H,

[129] Kennedy LG,

[130] O’Hea J,

[131] Mallorie P,

[132] et al.

[133] 19.↵
van der Linden S,
Valkenburg HA,
Cats A
. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361–8.
OpenUrl CrossRef PubMed

[134] van der Linden S,

[135] Valkenburg HA,

[136] Cats A

[137] 20.↵
Smolen JS,
Braun J,
Dougados M,
Emery P,
Fitzgerald O,
Helliwell P,
et al.
Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16.
OpenUrl Abstract/FREE Full Text

[138] Smolen JS,

[139] Braun J,

[140] Dougados M,

[141] Emery P,

[142] Fitzgerald O,

[143] Helliwell P,

[144] et al.

[145] 21.↵
van Tubergen A,
van der Heijde D,
Anderson J,
Landewé R,
Dougados M,
Braun J,
et al.
Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel. Ann Rheum Dis 2003;62:215–21.
OpenUrl Abstract/FREE Full Text

[146] van Tubergen A,

[147] van der Heijde D,

[148] Anderson J,

[149] Landewé R,

[150] Dougados M,

[151] Braun J,

[152] et al.

[153] 22.↵
Stone MA,
Inman RD,
Wright JG,
Maetzel A
. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. Arthritis Rheum 2004;51:316–20.
OpenUrl CrossRef PubMed

[154] Stone MA,

[155] Inman RD,

[156] Wright JG,

[157] Maetzel A

[158] 23.↵
Glintborg B,
Ostergaard M,
Krogh NS,
Dreyer L,
Kristensen HL,
Hetland ML
. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years’ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010;69:2002–8.
OpenUrl Abstract/FREE Full Text

[159] Glintborg B,

[160] Ostergaard M,

[161] Krogh NS,

[162] Dreyer L,

[163] Kristensen HL,

[164] Hetland ML

[165] 24.↵
Heinonen AV,
Aaltonen KJ,
Joensuu JT,
Lähteenmäki JP,
Pertovaara MI,
Romu MK,
et al.
Effectiveness and drug survival of TNF inhibitors in the treatment of ankylosing spondylitis: a prospective cohort study. J Rheumatol 2015;42:2339–46.
OpenUrl Abstract/FREE Full Text

[166] Heinonen AV,

[167] Aaltonen KJ,

[168] Joensuu JT,

[169] Lähteenmäki JP,

[170] Pertovaara MI,

[171] Romu MK,

[172] et al.

[173] 25.↵
Lorenzin M,
Ortolan A,
Frallonardo P,
Oliviero F,
Punzi L,
Ramonda R
. Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord 2015;16:166.
OpenUrl CrossRef PubMed

[174] Lorenzin M,

[175] Ortolan A,

[176] Frallonardo P,

[177] Oliviero F,

[178] Punzi L,

[179] Ramonda R

[180] 26.↵
Sieper J,
Lenaerts J,
Wollenhaupt J,
Rudwaleit M,
Mazurov VI,
Myasoutova L,
et al;
All INFAST Investigators
. Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 2014;73:108–13.
OpenUrl Abstract/FREE Full Text

[181] Sieper J,

[182] Lenaerts J,

[183] Wollenhaupt J,

[184] Rudwaleit M,

[185] Mazurov VI,

[186] Myasoutova L,

[187] et al;

[188] All INFAST Investigators

[189] 27.↵
Song IH,
Althoff CE,
Haibel H,
Hermann KG,
Poddubnyy D,
Listing J,
et al.
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012;71:1212–5.
OpenUrl Abstract/FREE Full Text

[190] Song IH,

[191] Althoff CE,

[192] Haibel H,

[193] Hermann KG,

[194] Poddubnyy D,

[195] Listing J,

[196] et al.

[197] 28.↵
Gossec L,
Portier A,
Landewé R,
Etcheto A,
Navarro-Compán V,
Kroon F,
et al.
Preliminary definitions of ‘flare’ in axial spondyloarthritis, based on pain, BASDAI and ASDAS-CRP: an ASAS initiative. Ann Rheum Dis 2016 Feb 4 (E-pub ahead of print).

[198] Gossec L,

[199] Portier A,

[200] Landewé R,

[201] Etcheto A,

[202] Navarro-Compán V,

[203] Kroon F,

[204] et al.

[205] 29.↵
Godfrin-Valnet M,
Puyraveau M,
Prati C,
Wendling D
. Flare in spondyloarthritis: thresholds of disease activity variations. Joint Bone Spine 2015;82:192–5.
OpenUrl CrossRef PubMed

[206] Godfrin-Valnet M,

[207] Puyraveau M,

[208] Prati C,

[209] Wendling D

[210] 30.↵
Wendling D,
Prati C
. Flare in axial spondyloarthritis. The dark side of the outcome. Ann Rheum Dis 2016 March 15 (E-pub ahead of print).

[211] Wendling D,

[212] Prati C

Main menu

User menu

Search

Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study

REFERENCES

In this issue

Citation Manager Formats

Keywords

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

Content

Resources

Subscribers

More

Main menu

User menu

Search

Predictors of Loss of Remission and Disease Flares in Patients with Axial Spondyloarthritis Receiving Antitumor Necrosis Factor Treatment: A Retrospective Study

REFERENCES

In this issue

Citation Manager Formats

Jump to section

Keywords

Related Articles

Cited By...

More in this TOC Section

Similar Articles

Keywords

Content

Resources

Subscribers

More